Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lunsekimig - Sanofi

Next Previous
Drug Profile

Lunsekimig - Sanofi

Alternative Names: Anti-IL-13 and TSLP - Sanofi; Anti-IL-13/TSLP - Sanofi; SAR-443765

Latest Information Update: 23 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Single-domain antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease
  • Phase II Asthma; Atopic dermatitis; Rhinosinusitis

Most Recent Events

  • 11 Mar 2026 Sanofi completes the phase II AIRCULES trial in Asthma (Treatment-experienced) in USA, Argentina, Brazil, Canada, Chile, China, India, Israel, Japan, Mexico, South Africa, South Korea, Turkey, United Kingdom (SC) (NCT06102005) (CTIS2023-503712-33-00)
  • 18 Sep 2025 Sanofi plans a phase III THESEUS trial for Chronic obstructive pulmonary disease (SC) in September 2025(NCT07190222)
  • 17 Sep 2025 Phase-III clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA, Australia, Canada, United Kingdom (SC) (NCT07190222)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top